Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies

Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies

Abstract Background Interpretation of rituximab efficacy for refractory idiopathic inflammatory myopathies (IIM) is hampered by the absence of a uniform definition of refractory myositis and clinical response. Therefore, rigorous criteria of refractoriness, together with a homogenous definition of c...

Full description

Bibliographic Details
Main Authors: Fernando Henrique Carlos de Souza, Renata Miossi, Júlio Cesar Bertacini de Moraes, Eloisa Bonfá, Samuel Katsuyuki Shinjo
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Advances in Rheumatology
Subjects:
Antibodies
Dermatomyositis
Myositis
Polymyositis
Rituximab
Online Access:http://link.springer.com/article/10.1186/s42358-018-0030-z

Internet

http://link.springer.com/article/10.1186/s42358-018-0030-z

Similar Items